Skip to main content

Table 1 Baseline characteristics

From: Acute reverse annular remodeling during MitraClip® therapy predicts improved clinical outcome in heart failure patients: a 3D echocardiography study

  All patients High Responder Low Responder p
Age (yrs ± SD) 70 ± 11 67 ± 25 72 ± 11 0.15
Male n (%) 29 (64) 15 (75) 14 (56) 0.19
BMI (kg/m2 ± SD) 27 ± 5 27 ± 5 27 ± 5 0.69
Grade of MR n (%)   0.86
 4+ 33 (73) 14 (70) 19 (76)  
 3+ 5 (11) 4 (20) 1 (4)  
 2+ 7 (16) 2 (10) 5 (20)  
NYHA n (%) 0.06
 IV 8 (18) 4 (20) 4 (16)  
 III–IV 11 (24) 8 (40) 3 (12)  
 III 15 (33) 5 (25) 10 (40)  
 II–III 8 (18) 3 (15) 5 (20)  
 II 3 (7) 0 3 (12)  
Previous interventions n (%)
 CABG or PCI 12 (27) 5 (25) 7 (28) 0.82
 Valve surgery 4 (9) 1 (5) 3 (12) 0.42
 ICD 13 (29) 8 (40) 5 (20) 0.15
 CRT 9 (20) 3 (15) 6 (24) 0.46
Comorbidities n (%)
 AF 30 (67) 9 (45) 21 (84) 0.005
 SR 21 (47) 12 (6) 9 (36) 0.11
 CAD 29 (64) 11 (55) 18 (72) 0.25
 Previous MI 15 (33) 5 25) 10 (40) 0.30
 COPD 8 (18) 5 (25) 3 (12) 0.27
 pHTN 29 (64) 14 (70) 15 (60) 0.51
 Logistic EuroSCORE (% ± SD) 17 ± 17 (6–21) 16 ± 17 133 ± 17 (6–19) 0.84
Medication n (%)
 ACE inhibitors/ARB 29 (64) 13 (65) 16 (64) 0.95
 AT1-antagonists 6 (13) 4 (20) 2 (8) 0.25
 Beta-blockers 41 (91) 18 (90) 23 (92) 0.82
 Loop diuretics 36 (80) 16 (80) 20 (80) 1
 Aldosterone antagonists 22 (49) 12 (60) 10 (40) 0.19
  1. AF atrial fibrillation, BMI Body Mass Index; CABG, coronary artery bypass graft, CAD coronar artery disease, COPD chronic obstructive pulmonary disease, CRT cardiac resynchronization therapy, ICD implantable cardioverter-defibrillator, MI myocardial infarction, MR mitral regurgitation, NYHA New York Heart Association, PCI percutaneous coronary intervention, pHTN pulmonary hypertension, SR sinus rhythm